Integra LifeSciences Holdings Corporation
IART
$22.37
-$1.58-6.60%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.61B | 1.56B | 1.57B | 1.53B | 1.54B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.61B | 1.56B | 1.57B | 1.53B | 1.54B |
| Cost of Revenue | 656.01M | 637.00M | 627.06M | 600.76M | 593.66M |
| Gross Profit | 954.52M | 927.92M | 939.44M | 928.84M | 947.92M |
| SG&A Expenses | 668.77M | 637.03M | 620.24M | 601.59M | 598.83M |
| Depreciation & Amortization | 14.23M | 13.54M | 12.99M | 12.31M | 12.38M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.43B | 1.38B | 1.35B | 1.30B | 1.29B |
| Operating Income | 177.12M | 189.02M | 220.96M | 231.49M | 251.88M |
| Income Before Tax | -18.24M | -11.92M | 27.05M | 46.06M | 81.07M |
| Income Tax Expenses | -11.29M | -5.38M | 3.40M | 5.83M | 13.33M |
| Earnings from Continuing Operations | -6.94 | -6.54 | 23.65 | 40.23 | 67.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.94M | -6.54M | 23.65M | 40.23M | 67.74M |
| EBIT | 177.12M | 189.02M | 220.96M | 231.49M | 251.88M |
| EBITDA | 318.02M | 316.21M | 356.94M | 354.42M | 375.39M |
| EPS Basic | -0.09 | -0.09 | 0.30 | 0.51 | 0.85 |
| Normalized Basic EPS | 1.06 | 1.20 | 1.47 | 1.57 | 1.72 |
| EPS Diluted | -0.09 | -0.09 | 0.29 | 0.50 | 0.83 |
| Normalized Diluted EPS | 1.06 | 1.20 | 1.47 | 1.57 | 1.72 |
| Average Basic Shares Outstanding | 308.01M | 309.55M | 312.79M | 316.35M | 320.49M |
| Average Diluted Shares Outstanding | 308.01M | 309.55M | 312.91M | 316.66M | 321.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
